The Ludwig Johns Hopkins team’s ADCs, which recognized the T cell receptor β-chain constant region 1 (TRBC1), selectively delivered a potent cytotoxin to the T cell cancers, leading to long-term cancer regressions and cures in pre-clinical models. The investigators hope that the ADCs can be tested in human clinical trials in the future.

https://www.ludwigcancerresearch.org/ludwig-link/september-2024/a-new-way-to-treat-t-cell-malignancies/